IMC Logo.jpg
US DoD Naval Medical Research Center Clinical Update
November 10, 2021 06:00 ET | Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
IMC Logo.jpg
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
November 11, 2020 06:00 ET | Immuron Limited
Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETECImmuron executes a Research Agreement with PCI Clinical Services to manufacture drug...
IMC Logo.jpg
Immuron Travelers’ Diarrhea Market Update
October 12, 2020 06:00 ET | Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
IMC Logo.jpg
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
July 20, 2020 06:00 ET | Immuron Limited
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...
IMC Logo.jpg
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
June 19, 2020 06:00 ET | Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...
IMC Logo.jpg
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
June 09, 2020 06:00 ET | Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
IMC Logo.jpg
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
June 12, 2019 07:00 ET | Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
IMC Logo.jpg
US Department of Defense Reports Travelan Protects Against Shigella in Primates
September 05, 2018 10:00 ET | Immuron Limited
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of...
IMC Logo.jpg
US Department of Defense Research Collaboration Moves Forward
July 24, 2018 06:28 ET | Immuron Limited
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned by the US Department of Defense to evaluate Travelan®’s ability to...
IMC Logo.jpg
Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
April 23, 2018 09:30 ET | Immuron Limited
Key Highlights: US Travelan® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales (End March 2018) climbed to...